دورية أكاديمية
أعرض في EDS

Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors.

التفاصيل البيبلوغرافية
العنوان: Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors.
المؤلفون: Costin D; Department of Medical Sciences II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Clinical Rehabilitation Hospital, 700661 Iasi, Romania., Burlui AM; Department of Medical Sciences II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Clinical Rehabilitation Hospital, 700661 Iasi, Romania., Cardoneanu A; Department of Medical Sciences II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Clinical Rehabilitation Hospital, 700661 Iasi, Romania., Macovei LA; Department of Medical Sciences II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Clinical Rehabilitation Hospital, 700661 Iasi, Romania., Rezus C; Department of Internal Medicine, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; 'Sfantul Spiridon' Emergency Hospital, 700111 Iasi, Romania., Bratoiu I; Department of Medical Sciences II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Clinical Rehabilitation Hospital, 700661 Iasi, Romania., Richter P; Department of Medical Sciences II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Clinical Rehabilitation Hospital, 700661 Iasi, Romania., Mihai IR; Department of Medical Sciences II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Clinical Rehabilitation Hospital, 700661 Iasi, Romania., Gherasim A; Department of Medical Sciences II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; 'Sfantul Spiridon' Emergency Hospital, 700111 Iasi, Romania., Danielescu C; Department of Surgery II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; 'Profesor Dr. Nicolae Oblu' Clinical Emergency Hospital, 700309 Iasi, Romania., Rezus E; Department of Medical Sciences II, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Clinical Rehabilitation Hospital, 700661 Iasi, Romania.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 27; Vol. 25 (13). Date of Electronic Publication: 2024 Jun 27.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Psoriasis*/genetics , Psoriasis*/drug therapy , Polymorphism, Single Nucleotide* , Tumor Necrosis Factor Inhibitors*/therapeutic use , Tumor Necrosis Factor Inhibitors*/adverse effects, Humans ; Genetic Predisposition to Disease ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/genetics
مستخلص: TNF inhibitors (TNFi) have revolutionized the therapeutic management of various chronic immune-mediated inflammatory diseases. Despite their known benefits, these therapies are related to paradoxical adverse effects (PAEs), including paradoxical psoriasis (PP). Although the underlying mechanism remains somewhat unclear, some theories suggest that genetic factors, particularly certain single-nucleotide polymorphisms (SNPs), may play an important role. The present review aimed to research and analyze recent findings regarding the pathomechanisms involved in the appearance of PP and the association between various genetic factors and PP in individuals treated with TNFi. We performed a literature search and found that certain genes (IL23R , TNF , FBXL19 , CTLA4 , SLC12A8 , TAP1 ) are strongly associated with the occurrence of PP in pediatric and adult patients during therapy with TNFi. The identification of the specific SNPs involved in the appearance of PP and other PAEs in patients treated with TNFi for various diseases and in different populations may later favor the recognition of those patients at a high risk of developing such adverse effects and could guide personalized therapeutic strategies in future years.
References: Int J Mol Sci. 2023 Jun 07;24(12):. (PMID: 37372997)
Gut. 2014 Apr;63(4):567-77. (PMID: 23468464)
Dermatol Ther (Heidelb). 2023 Apr;13(4):911-933. (PMID: 36929119)
J Drugs Dermatol. 2024 Feb 1;23(2):e60-e63. (PMID: 38306123)
Int J Immunogenet. 2020 Feb;47(1):41-49. (PMID: 31342641)
Br J Dermatol. 2013 Jul;169(1):47-52. (PMID: 23521130)
Medicine (Baltimore). 2021 Oct 22;100(42):e27510. (PMID: 34678884)
J Pediatr Gastroenterol Nutr. 2013 May;56(5):512-8. (PMID: 23274341)
Br J Dermatol. 2009 Nov;161(5):1081-8. (PMID: 19681863)
Curr Probl Dermatol. 2018;53:49-63. (PMID: 29131037)
Clin Immunol. 2019 Sep;206:108251. (PMID: 31445171)
Joint Bone Spine. 2018 Jan;85(1):53-57. (PMID: 28115268)
Int J Mol Sci. 2023 May 03;24(9):. (PMID: 37175894)
Br J Anaesth. 2009 Apr;102(4):453-62. (PMID: 19258380)
Clin Cosmet Investig Dermatol. 2020 Aug 14;13:561-578. (PMID: 32884319)
Aliment Pharmacol Ther. 2016 Mar;43(6):697-704. (PMID: 26806281)
Dermatol Ther (Heidelb). 2020 Aug;10(4):869-879. (PMID: 32447747)
Expert Rev Clin Immunol. 2014 Jan;10(1):159-69. (PMID: 24325385)
Semin Arthritis Rheum. 2020 Feb;50(1):36-41. (PMID: 31350056)
Immunotherapy. 2015;7(7):717-20. (PMID: 26250408)
Indian J Dermatol Venereol Leprol. 2016 Jan-Feb;82(1):7-12. (PMID: 26728803)
Cureus. 2022 Jan 11;14(1):e21126. (PMID: 35036238)
J Psoriasis Psoriatic Arthritis. 2019 Apr;4(2):70-80. (PMID: 31093599)
PLoS One. 2016 Jul 19;11(7):e0159539. (PMID: 27434104)
Front Pharmacol. 2019 Mar 26;10:282. (PMID: 30971924)
Clin Exp Dermatol. 2018 Jan;43(1):19-26. (PMID: 28940220)
Front Immunol. 2024 Feb 20;15:1341632. (PMID: 38444845)
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e71-e73. (PMID: 27291419)
Ann Pharmacother. 2017 May;51(5):388-393. (PMID: 27920336)
J Allergy Clin Immunol. 2016 Jan;137(1):19-27. (PMID: 26768759)
Front Med (Lausanne). 2023 May 31;10:1197273. (PMID: 37324147)
Fac Rev. 2021 Jul 27;10:62. (PMID: 34409425)
RMD Open. 2016 Jul 15;2(2):e000239. (PMID: 27493788)
J Pathol Clin Res. 2020 Jan;6(1):55-68. (PMID: 31577850)
Int J Mol Sci. 2020 Oct 23;21(21):. (PMID: 33114187)
An Bras Dermatol. 2016 Sep-Oct;91(5 suppl 1):137-139. (PMID: 28300922)
Dermatol Ther. 2020 Nov;33(6):e14225. (PMID: 32844554)
Expert Opin Drug Saf. 2017 Nov;16(11):1255-1271. (PMID: 28854831)
J Transl Autoimmun. 2023 Sep 06;7:100211. (PMID: 37731549)
J Dermatol. 2020 Feb;47(2):104-113. (PMID: 31833093)
Am J Clin Dermatol. 2020 Jun;21(3):355-370. (PMID: 32008176)
Cureus. 2023 Aug 1;15(8):e42791. (PMID: 37664349)
Clin Immunol. 2019 Sep;206:23-32. (PMID: 30394352)
Acta Derm Venereol. 2020 Jan 23;100(3):adv00030. (PMID: 31971603)
J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1792-1799. (PMID: 28585342)
Dtsch Arztebl Int. 2022 Feb 11;119(6):88-95. (PMID: 34939919)
Ann Rheum Dis. 2003 Sep;62(9):829-34. (PMID: 12922954)
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):700-6. (PMID: 22935567)
Front Immunol. 2018 Nov 28;9:2746. (PMID: 30555460)
Adv Sci (Weinh). 2021 Aug;8(15):e2004433. (PMID: 34114369)
Pharmacogenomics J. 2016 Aug;16(4):336-40. (PMID: 26194362)
Arthritis Res Ther. 2018 Oct 12;20(1):229. (PMID: 30314507)
Cytokine Growth Factor Rev. 2015 Feb;26(1):25-33. (PMID: 25434285)
Actas Dermosifiliogr (Engl Ed). 2018 Nov;109(9):791-800. (PMID: 29903464)
Biomedicines. 2022 Feb 16;10(2):. (PMID: 35203664)
Front Immunol. 2022 Mar 01;13:847160. (PMID: 35300336)
Immunity. 2018 Feb 20;48(2):202-213. (PMID: 29466753)
Front Immunol. 2021 Dec 15;12:788940. (PMID: 34975883)
Cytokine. 2018 Jan;101:14-18. (PMID: 27531077)
Nat Commun. 2018 Jan 2;9(1):25. (PMID: 29295985)
Biomedicines. 2022 Jun 23;10(7):. (PMID: 35884790)
J Int Med Res. 2023 Sep;51(9):3000605231200270. (PMID: 37773730)
Methods Mol Biol. 2021;2248:155-165. (PMID: 33185874)
J Am Acad Dermatol. 2020 Dec;83(6):1599-1605. (PMID: 32592879)
Ann Agric Environ Med. 2020 Sep 11;27(3):335-342. (PMID: 32955211)
فهرسة مساهمة: Keywords: gene; genetic polymorphisms; genetic predisposition; paradoxical adverse effects; paradoxical psoriasis; tumor necrosis factor-alpha inhibitors
المشرفين على المادة: 0 (Tumor Necrosis Factor Inhibitors)
0 (Tumor Necrosis Factor-alpha)
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240718
رمز التحديث: 20240718
مُعرف محوري في PubMed: PMC11241744
DOI: 10.3390/ijms25137018
PMID: 39000125
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25137018